The "Relief of Chronic Pain Act of 2025" seeks to enhance access to non-opioid pain management drugs for individuals with chronic pain conditions under Medicare Part D. Starting January 1, 2026, the bill mandates that for qualifying non-opioid chronic pain management drugs, the Part D deductible will not apply, and these drugs must be placed on the lowest cost-sharing tier . A "qualifying non-opioid chronic pain management drug" is defined as an FDA-approved non-opioid drug or biological product for chronic pain that does not act on opioid receptors, lacks therapeutically equivalent alternatives, and meets specific cost thresholds. The legislation also lists several chronic pain conditions, such as fibromyalgia and neuropathic pain, that are covered by these provisions. Additionally, the bill prohibits prescription drug plans from imposing certain utilization management restrictions on these non-opioid treatments. For plan years beginning in 2026, plans cannot require step therapy that mandates opioid use before a non-opioid drug, nor can they require prior authorization for these qualifying non-opioid chronic pain management drugs, aiming to remove barriers to their use.